PepTherDia: database and structure composition analysis of approved peptide therapeutics and diagnostics

被引：86

作者：

D'Aloisio, Vera ^{[1
]}

Dognini, Paolo ^{[1
]}

Hutcheon, Gillian A. ^{[1
]}

Coxon, Christopher R. ^{[2
]}

机构：

[1] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Fac Sci, Liverpool L3 3AF, Merseyside, England

[2] Heriot Watt Univ, Inst Chem Sci, Sch Engn & Phys Sci, Edinburgh EH14 4AS, Midlothian, Scotland

来源：

DRUG DISCOVERY TODAY | 2021年 / 26卷 / 06期

关键词：

CYCLIC-PEPTIDES; L-TRYPTOPHAN; PRECURSORS; ANALOGS;

D O I：

10.1016/j.drudis.2021.02.019

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

As of 2020, there were >100 approved peptides with therapeutic or diagnostic applications. However, a complete database providing information on marketed peptides is not freely available, making the peptide chemists' job of designing future peptide drug candidates challenging. Unlike the rules for small-molecule drugs, there is no general set of guidelines for designing a successful peptide-based drug. In this review, together with our freely available database (PepTherDia, http://peptherdia.herokuapp.com), we provide insights into what a successful peptide therapeutic or diagnostic agent looks like and lay the foundation for establishing a set of rules to help future medicinal chemists to design peptide candidates with increased approval rates.

引用

页码：1409 / 1419

页数：11

共 59 条

[1]

[Anonymous], 2012, Drug Discov Today Technol, V9, pe1, DOI 10.1016/j.ddtec.2011.07.005

[2] Cyclic peptides from linear unprotected peptide precursors through thiazolidine formation [J].